Results 71 to 80 of about 2,302 (210)

Renin-angiotensin system blockers: therapy of choice in patients with arterial hypertension and heart failure

open access: yesМедицинский совет, 2013
One of the major challenges in the modern medicine is chronic heart failure (CHF) characterized by high incidence, really unfavourable prognosis and high cost of treatment.
G. N. Gorokhovskaya   +2 more
doaj   +1 more source

Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. [PDF]

open access: yes, 2002
The aim of this study is to compare the long-term effect of amlodipine and fosinopril in monotherapy or in combination on urinary albumin excretion (UAE) in hypertensive diabetic patients.We selected 453 hypertensive patients with type 2 diabetes and ...
PRETI, PAOLA STEFANIA   +13 more
core  

VALUE OF THERAPEUTIC EQUIVALENCE IN SUBSTITUTION OF ORIGINAL DRUG WITH GENERIC BY EXAMPLE OF FOSINIPRIL

open access: yesРациональная фармакотерапия в кардиологии, 2016
Aim. To study the therapeutic equivalence of original and generic fosinopril in patients with arterial hypertension (HT) of 1-2 degrees, and to evaluate the cost effectiveness of original drug substitution with generic. Material and methods.
N. P. Kutishenko   +3 more
doaj   +1 more source

Nifedipine versus fosinopril in uninephrectomized diabetic rats

open access: yes, 1992
Nifedipine versus fosinopril in uninephrectomized diabetic rats. Antihypertensive agents have been shown to exert inequivalent effects on glomerular injury in experimental renal disease models.
Rennke, Helmut G.   +6 more
core   +1 more source

Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives

open access: yes, 1990
Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Hypertension and renal mass reduction induce glomerular hypertension (GH), hyperfiltration (HF) and renal injury.
Pérez-Grovas, Héctor   +5 more
core   +1 more source

THE PLACE OF FOSINOPRIL IN EVIDENCE-BASED TREATMENT OF PATIENTS WITH ARTERIAL HYPERTENSION

open access: yesМедицинский совет, 2017
Cardiovascular diseases (CVD) remain the main cause of mortality in the world. [1] At the same time, arterial hypertension (AH) is one of the most common CV pathologies, which, according to foreign researchers, affects about 30–45% of the general ...
S. A. Berns, R. I. Stryuk
doaj   +1 more source

A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough

open access: yes, 1995
OBJECTIVE: Cough frequency and severity with fosinopril and enalapril were assessed in hypertensive patients with previous angiotensin-converting enzyme inhibitor (ACEI)-associated cough.
Jallad, Nader   +6 more
core   +1 more source

CURRENT PROSPECTS FOR THE TREATMENT OF DIABETES COMPLICATIONS

open access: yesМедицинский совет, 2016
Arterial hypertension (AH) complicates the course of diabetes mellitus (DM) of both the 1st and 2nd type. In patients with diabetes type 1, the main cause of AH is diabetic nephropathy.
M. Y. OGARKOV, Y. V. KOVALEVA
doaj   +1 more source

Therapeutic effects of fosinopril - ACE inhibitor

open access: yesКардиоСоматика, 2015
The review article dials with the characteristics of fosinopriltherapeutic features, apparently associated with the fact that it contains phosphorus. It has special specter possessing the numerous of organotropic effects and good tolerability and safety,
D. M Aronov
doaj  

Selection of an ACE inhibitor in clinical practice

open access: yesМедицинский совет, 2014
Currently, ACE inhibitors are considered to be the gold standard in the treatment of cardiovascular diseases. They all have cardio-, vaso- and nephroprotective and positive metabolic effects; however, despite the large number of the so-called class ...
OD Ostroumova   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy